The global Acetaminophen API Market is anticipated to surpass USD 1,180.4 million in 2023.
With the drug coming in very handy as a palliative in pain relief and in combination with other drugs in a plethora of medical conditions, the drug is available over the counter (OTC) in the form of extended-release tablets exuding analgesic effects, the overall demand for acetaminophen market is projected to exhibit a CAGR of 3.4% between 2023 and 2033 totaling USD 1,648.2 million by 2033.
Attributes | Details |
---|---|
Acetaminophen API Market Share (2022) | USD 137.2 million |
Acetaminophen API Market Share (2023) | USD 1,180.4 million |
Acetaminophen API Market Share (2033) | USD 1,648.2 million |
Acetaminophen API Market Share (2023 to 2033) | 3.4% |
Acetaminophen API, commonly known as Paracetamol or Tylenol, is a drug that is used as a first line of defense in any painful condition. This miracle drug displays antipyretic and analgesics effect when associated with various other drugs. Acetaminophen is found in over-the-counter (OTC) as with plenty of drugs which include pain relievers and sleep anxiety pills.
Discovered in 1877, the drug is typically used for mild to moderate pain. It is generally prescribed either individually or in association with cold medication.
The name 'Paracetamol' is approved by the International Non-proprietary, Britain and Australia, while Acetaminophen is the name which is approved and used in the United States and Japan. Tylenol is an appropriate analgesic choice for people suffering from hypertension.
The usage of acetaminophen grade is higher due to its wide utilization in the drug development process. While it is widely used in the pharmaceutical industry as a pain killer, it offers a lucrative opportunity for the growth of the Acetaminophen API market in the forecasted period.
Aside from this, the acetaminophen drug is combined with various drugs and is available in various forms, but it is mostly available in the form of extended-release tablets for showing analgesic effects.
These drugs are administered to patients who are habituated to ingesting salicylates and those suffering from hypersensitive propensities, including bronchial asthmatics. It comes under the NSAIDs (nonsteroidal anti-inflammatory drugs) category because of its capacity to repress the cyclooxygenase (COX) pathways.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights, demand for acetaminophen API experienced sales incline at a CAGR of 2.1% from 2018 to 2022. Increasing awareness regarding palliative care in critically ill patients is boosting the adoption of analgesics for pain management.
Since the prevalence of pain is over 75% in advanced disease conditions, sales of the drug are expected to gain traction in the forthcoming years.
Acetaminophen usage is higher due to its wide utilization in the drug development process. While it is widely used in the pharmaceutical industry as a pain killer, it offers a lucrative opportunity for the growth of the Acetaminophen API market in the forecast period.
Besides, acetaminophen is combined with various drugs and is available in various forms, but it is mostly available in the form of extended-release tablets for showing analgesic effects. But heavy usage of this drug can cause serious adverse effects & can build toxicity, leading to other diseases.
At the same time, limitations on the export of key drug candidates may hamper future expansion prospects. For instance, the Indian government has put limitations on the export of 27 active pharmaceutical ingredients (APIs) and completed portions of drugs made with those APIs since the outbreak of COVID-19.
Johnson and Johnson's (New Brunswick, NJ, United States) Tylenol (acetaminophen/paracetamol) is among the medications whose supply chains were impacted.
The request may influence worldwide pharmaceutical supply chains. India is a crucial area of pharmaceutical manufacturing for the drug market in different countries. The nation houses drug manufacturing units possessed by contract fabricating associations (CMOs) and others claimed by local and global biopharma organizations for in-house manufacturing.
Rising cases of chronic diseases to rope in significant growth
Rising cases of chronic diseases and conditions that require pain management solutions regularly are vital in improving market growth.
Additionally, also increasing need for medicines for pain relief, rising health awareness among consumers, rising applications of acetaminophen in the dye industry and chemical industry, and rising recommendations of acetaminophen by doctors for mild pain and fever are the key factors among others, driving the acetaminophen (Paracetamol) market.
But heavy usage of this drug can cause serious adverse effects & can build toxicity, leading to other diseases.
According to CDC (Center for Disease Control), in 2019, 20.2% of adults had chronic pain, and 7.1% had chronic pain that discouraged work activities. Similarly, in the United Kingdom, around 22% of patients with diabetes were found to have peripheral neuropathic pain.
Paracetamol can be combined with other pain management drugs sold through prescription only, which is expected to continue boosting sales.
Furthermore, rising technological advancements and modernization in the production of paracetamol, rising research and development activities in the healthcare sector, and rising emerging markets with an increasing geriatric population base may further open up opportunities for the acetaminophen (Paracetamol) market in the forecasted period of 2021 to 2028.
Tylenol does not interfere with high BP medications as other drugs do.
Increasing access to OTC drugs has a telling impact on the acetaminophen market.
The increasing availability of generic medicines amid intense competition coupled with the growing popularity of sustainable chemistry are the key factors, among others, that may obstruct the market growth and may further challenge the growth of the acetaminophen (Paracetamol) market in the forecast period mentioned above.
Acetaminophen toxicity may lead to acute liver failure, although various risk factors raise the probability of acute liver damage, such as alcohol, and the intake of such substances, increases the risk of liver failure after consuming acetaminophen.
IV administered Acetaminophen to remain prominent in managing pain
Intravenous (IV) acetaminophen is increasingly used worldwide for pain control for various indications. There is no accurate analysis regarding intravenous administration being more suitable over oral acetaminophen medication. The category ushers in amplified growth.
Acetaminophen injection is used together with other medicines (e.g., narcotic pain relievers) to relieve moderate to severe pain.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Heart ailments not unheeded with acetaminophen administration
North America accounted for 33.4% of the global revenue share in the acetaminophen API market as of 2022, with the United States being the leading contributor.
The research concludes that over 90 million American adults have at least one type of cardiovascular disease. Hence, when recommending an analgesic, it's important to consider patients' heart risks.
The combination of certain pain relievers with some medicinal therapies can interfere with cardiovascular treatment. Because of its safety and analgesic efficacy, the American Heart Association has identified acetaminophen as a first-line pain relief option for patients with or at high risk for cardiovascular disease.
North America is the second-leading region in terms of growth in the acetaminophen (Paracetamol) market due to rising healthcare spending and the availability of affordable drugs in this region.
Rapid development and advancements, along with the changing topography, are going to offer a lucrative opportunity for the growth of the acetaminophen API market in North America during the forecasted period. Acetaminophen is also widely used and prescribed in North America.
Pain management to reaffirm growth in the European region
Europe is the region under the scanner in terms of growth in the acetaminophen (Paracetamol) market due to the rising need to manage pain and growing awareness in this region. In Germany, ibuprofen, naproxen, and paracetamol are widely available OTC at offline and internet pharmacies. Europe captured 26.2% of global market shares in 2022.
The wide availability of the drugs leads to intentional or unintentional overdose that affects the body and its functioning. Acute liver failure is a severe form of acute liver injury that can progress to multiple organs and causes failure. The overall incidence of acute liver failure in developed countries on a yearly basis was found to be 1 to 6 per million people.
In Germany, almost 200 to 500 cases of acute liver failure occur annually, affecting women more than men, accounting for 52% to 63% of cases. Furthermore, Germany invests significantly in healthcare research and infrastructure among all the nations that are a part of the European Union.
According to the Federal Statistical Office, health expenditure in Germany accounted for USD 440. 09 billion in 2019, which was one of the highest healthcare expenditures for healthcare among the relative EU member states. This signifies a pivotal market for acetaminophen.
BOC Sciences, Tianjin Bofa Acetaminophen, Mallinckrodt Plc., Kemcolour International, Changshu Huagang Acetaminophen, Haohua Industry, Kangle Acetaminophen, Angene International Limited, and Anhui BBCA Acetaminophen are some prominent acetaminophen API manufacturers. With so many players present in the industrial growth of the acetaminophen market, the market remains highly competitive.
Recent Developments Observed by FMI:
Key Players in the Global Market:
Attributes | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2018 to 2022 |
Market Analysis | USD million for Value |
Key Regions Covered | North America; Latin America; Europe; Asia Pacific; The Middle East & Africa (MEA) |
Key Countries Covered | United States, Canada, Germany, United Kingdom, Nordic, Russia, BENELUX, Poland, France, Spain, Italy, Czech Republic, Hungary, Rest of EMEAI, Brazil, Peru, Argentina, Mexico, South Africa, Northern Africa, GCC Countries, China, Japan, South Korea, India, ASEAN, Thailand, Malaysia, Indonesia, Australia, New Zealand, Others |
Key Segments Covered | Type, End User, Product Form, Region |
Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Trend Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The acetaminophen API market is slated to attain USD 1,180.4 million in 2023.
The market demand of acetaminophen API is 3.4% CAGR through 2033.
IV administered acetaminophen is a prominent product type in the market.
North America holds market monopoly in the acetaminophen API market.
Tianjin Bofa Acetaminophen, Mallinckrodt plc, and Kemcolour International are key manufacturers.
Explore Healthcare Insights
View Reports